This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- m-Chlorophenylpiperazine
- DrugBank Accession Number
- DB12110
- Background
m-Chlorophenylpiperazine has been used in trials studying the treatment of Alcoholism.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for m-Chlorophenylpiperazine (DB12110)
- Weight
- Average: 196.677
Monoisotopic: 196.076726133 - Chemical Formula
- C10H13ClN2
- Synonyms
- 1-(3-chlorophenyl)piperazine
- M-CPP
- MCPP
- External IDs
- J227.960F
- NSC-49307
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism U5-hydroxytryptamine receptor 2C agonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Hover over products below to view reaction partners
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with 1,2-Benzodiazepine. Acenocoumarol The risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with Acenocoumarol. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with m-Chlorophenylpiperazine. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with m-Chlorophenylpiperazine. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with m-Chlorophenylpiperazine. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with m-Chlorophenylpiperazine. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with m-Chlorophenylpiperazine. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with m-Chlorophenylpiperazine. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with m-Chlorophenylpiperazine. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with m-Chlorophenylpiperazine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key m-Chlorophenylpiperazine dihydrochloride MY02G3EAXQ 51639-49-7 OSZCTRWSGNWWBL-UHFFFAOYSA-N m-Chlorophenylpiperazine hydrochloride 7IM2GS7ILV 13078-15-4 MHXPYWFZULXYHT-UHFFFAOYSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- Phenylpiperazines
- Alternative Parents
- N-arylpiperazines / Dialkylarylamines / Aniline and substituted anilines / Chlorobenzenes / Aryl chlorides / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
- Substituents
- Amine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid / Chlorobenzene / Dialkylarylamine / Halobenzene
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- N-arylpiperazine, monochlorobenzenes (CHEBI:10588)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- REY0CNO998
- CAS number
- 6640-24-0
- InChI Key
- VHFVKMTVMIZMIK-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2
- IUPAC Name
- 1-(3-chlorophenyl)piperazine
- SMILES
- ClC1=CC(=CC=C1)N1CCNCC1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0061008
- KEGG Compound
- C11738
- PubChem Compound
- 1355
- PubChem Substance
- 347828411
- ChemSpider
- 1314
- BindingDB
- 50001915
- ChEBI
- 10588
- ChEMBL
- CHEMBL478
- ZINC
- ZINC000000004285
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Alcohol Dependency 1 2 Completed Treatment Cocaine Related Disorders 1 1 Completed Treatment Cocaine Related Disorders 1 Not Available Terminated Basic Science Eating Behaviors / Obesity 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 3.12 mg/mL ALOGPS logP 2.07 ALOGPS logP 2.15 Chemaxon logS -1.8 ALOGPS pKa (Strongest Basic) 8.87 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 15.27 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 56.05 m3·mol-1 Chemaxon Polarizability 20.87 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
- Gene Name
- HTR2C
- Uniprot ID
- P28335
- Uniprot Name
- 5-hydroxytryptamine receptor 2C
- Molecular Weight
- 51820.705 Da
References
- Gibson EL, Barnfield AM, Curzon G: Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects. Neuropharmacology. 1994 Mar-Apr;33(3-4):457-65. [Article]
Drug created at October 20, 2016 21:22 / Updated at June 12, 2020 16:53